UpFront,Frontline Gastroenterology

当前位置： X-MOL 学术 › Frontline Gastroenterol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

UpFront
Frontline Gastroenterology ( IF 2.4 ) Pub Date : 2024-09-01 , DOI: 10.1136/flgastro-2024-102838
R Mark Beattie

There are ever-increasing therapeutic options for patients with ulcerative colitis, but licensing and availability for children and young people are often years behind those aged >18 years. In this issue, Ashton and colleagues review the evidence. This includes a comprehensive discussion of the standard ‘advanced’ therapies—infliximab and adalimumab. The authors review the ‘newer’ therapies including vedolizumab, ustekinumab, tofacitinab and upadacitinab where the evidence is (mostly) from adults with increasing use in patients

中文翻译：

预先

溃疡性结肠炎患者的治疗选择不断增加，但儿童和青少年的许可和可获得性往往落后于 18 岁以上的患者数年。在本期中，阿什顿和同事回顾了证据。这包括对标准“先进”疗法——英夫利昔单抗和阿达木单抗的全面讨论。作者回顾了“较新”的疗法，包括维多珠单抗、乌特克单抗、托法替尼和乌达西替尼，其中证据（大部分）来自成人，且在患者中的使用越来越多

更新日期：2024-08-08

点击分享查看原文

点击收藏

阅读更多本刊新发论文